BISOPROLOL FUMARATE

Post-LOE

bisoprolol fumarate

Aurobindo Pharma

ANDAORALTABLET

Approved

Apr 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

BISOPROLOL FUMARATE (bisoprolol fumarate) by Aurobindo Pharma is clinical pharmacology bisoprolol fumarate is a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Approved for the management of hypertension, hypertension. First approved in 2025.

Drug data last refreshed 19h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Bisoprolol fumarate is a beta 1 -selective (cardioselective) adrenoceptor blocking agent without significant membrane stabilizing activity or intrinsic sympathomimetic activity in its therapeutic dosage range. Cardioselectivity is not absolute, however, and at higher doses (≥…

Worked on BISOPROLOL FUMARATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (1)

NCT05288400Phase 3Completed

Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.

Started May 2018

150 enrolled

Essential Hypertension

BISOPROLOL FUMARATE

Mechanism of Action

Indications (2)

Clinical Trials (1)